5 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
TTWO Take-Two Interactive Software, Inc. $131.48 $14.97B Uptrend
Article Searches
Kamada to Begin Phase III Study for Inhaled AAT Product in 2H http://www.zacks.com/stock/news/384736/kamada-to-begin-phase-iii-study-for-inhaled-aat-product-in-2h?cid=CS-ZC-FT-384736 Apr 17, 2019 - Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.
What's in the Cards for Sunesis (SNSS) This Earnings Season? http://www.zacks.com/stock/news/406478/whats-in-the-cards-for-sunesis-snss-this-earnings-season?cid=CS-ZC-FT-406478 May 01, 2019 - Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.
Takeda down 2% on underwhelming TAK-788 data https://seekingalpha.com/news/3464620-takeda-2-percent-underwhelming-takminus-788-data?source=feed_news_all May 16, 2019 - Investors appear unmoved with interim data from an open-label Phase 1/2 clinical trial evaluating Takeda's (TAK -2.4%) oral TKI inhibitor TAK-788 in non-small cell lung cancer (NSCLC) patients
Company News For Mar 5, 2019 http://www.zacks.com/stock/news/357738/company-news-for-mar-5-2019?cid=CS-ZC--357738 Mar 05, 2019 - Companies in the news are; PLCE, BIIB, NITE, ASND and TAK
Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark http://www.zacks.com/stock/news/404524/seattle-genetics-sgen-q1-loss-narrows-revenues-top-mark?cid=CS-ZC-FT-404524 Apr 26, 2019 - Seattle Genetics (SGEN) betters loss estimates in Q1 and also rides high on revenue beat.

Pages: 1

Page 1